Related Experiment Videos
Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma
1Department of Orthopedic Surgery, Center for Adult Diseases, Osaka, Japan.
Abstract:
We treated a murine osteosarcoma cell line, LM8, which preferentially metastasizes to the lungs, with a new angiogenesis inhibitor, TNP-470, to evaluate the efficacy of this compound in the suppression of pulmonary metastasis of osteosarcoma. In an in vivo experiment, tumor cells were inoculated i.v. into C3H mice, and TNP-470 or vehicle alone (control group) was administered s.c. every day for 3 weeks. In the TNP-470-treated groups, both the number of pulmonary metastatic nodules and the lung wet weight were significantly reduced in a dose-dependent manner. Similarly, vascular density in the metastatic tumors estimated by immunohistochemical staining with anti-von-Willebrand factor antibody as an endothelial marker were significantly reduced. No severe side-effects were found. In an in vitro experiment, viable tumor cells were counted after 3 days' treatment with TNP-470. The 50% inhibitory concentration was 0.6 ng/ml for LM8, which was more sensitive than other tumor cells previously reported. Our results show that TNP-470 suppresses the pulmonary metastasis of LM8 and suggest that both its anti-angiogenic activity and cytostatic activity towards LM8 are responsible for the antitumor effect.
Insights
TNP-470, a novel angiogenesis inhibitor, effectively suppressed lung metastasis in murine osteosarcoma models. This compound demonstrated significant anti-tumor effects through both anti-angiogenic and cytostatic mechanisms.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis Research
Background:
- Osteosarcoma is a primary bone cancer with a high propensity for lung metastasis.
- Angiogenesis inhibitors are a promising therapeutic strategy for managing metastatic cancers.
Purpose of the Study:
- To evaluate the efficacy of TNP-470, a novel angiogenesis inhibitor, in suppressing pulmonary metastasis of osteosarcoma.
- To investigate the anti-angiogenic and cytostatic effects of TNP-470 on osteosarcoma cells.
Main Methods:
- In vivo studies involved intravenous inoculation of LM8 osteosarcoma cells into C3H mice, followed by daily subcutaneous administration of TNP-470 or vehicle control for 3 weeks.
- Pulmonary metastasis was assessed by counting metastatic nodules and measuring lung wet weight.
- Vascular density in metastatic tumors was evaluated using immunohistochemical staining for von Willebrand factor.
- In vitro studies assessed the cytostatic effect of TNP-470 on LM8 cells by counting viable cells after treatment.
Main Results:
- TNP-470 treatment significantly reduced the number of pulmonary metastatic nodules and lung wet weight in a dose-dependent manner.
- Vascular density within metastatic tumors was significantly decreased in TNP-470 treated groups.
- TNP-470 exhibited potent cytostatic activity against LM8 cells in vitro, with a 50% inhibitory concentration of 0.6 ng/ml.
- No severe side-effects were observed during the treatment period.
Conclusions:
- TNP-470 effectively suppresses pulmonary metastasis of osteosarcoma in a murine model.
- The anti-tumor effects of TNP-470 are attributed to its dual action: inhibiting angiogenesis and exerting cytostatic effects on osteosarcoma cells.
- TNP-470 shows potential as a therapeutic agent for osteosarcoma with pulmonary metastasis.